iron sulphate

Phase 3Small molecule

PPierre Fabre Pharma GmbH

iron sulphate is one of 341 small molecule programs targeting Blood Transfusion. It is currently in Phase 3.

Indications

Total Trials

Active Trials

340

Competitors

Pipeline

Status by Indication[3][1]

Indication

Blood TransfusionActive, not recruiting

Nasopharyngeal CarcinomaActive, not recruiting

Hip FractureActive, not recruiting

Restless Legs SyndromeActive, not recruiting

Cardiac TransplantActive, not recruiting

Iron Deficiency AnemiaActive, not recruiting

Total Knee ArthroplastyActive, not recruiting

HypophosphatemiaActive, not recruiting

AnemiaActive, not recruiting

Coronary Artery BypassActive, not recruiting

Blood TransfusionPhase 1

Active, not recruiting

Nasopharyngeal CarcinomaPhase 2

Active, not recruiting

Hip FracturePhase 3

Active, not recruiting

Restless Legs SyndromePhase 2

Active, not recruiting

Cardiac TransplantPhase 2/Phase 3

Active, not recruiting

Iron Deficiency AnemiaPhase 3

Active, not recruiting

Total Knee ArthroplastyPreclinical

Active, not recruiting

HypophosphatemiaPhase 3

Active, not recruiting

AnemiaPreclinical

Active, not recruiting

Coronary Artery BypassPhase 3

Active, not recruiting

Showing 10 of 14 indications

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

iron sulphate

PPierre Fabre Pharma GmbH

Phase 3

1 2

Bayer Aspirin

Bayer

Preclinical

2 3

Amidate

Pfizer

Preclinical

1 4

Brethine

Sanofi

Preclinical

1 5

Medrol

Pfizer

Preclinical

1 6

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

4 7

Xifaxan

SSalix

Preclinical

2 8

Oraverse

LLife Extension Foundation Inc.

Preclinical

1 9

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 10

Alpha-Glucosidase Inhibitors

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Kidney Disease3 trials

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease

Completed·PPharmacosmos A/S·Phase 3·NCT02940860·1,538 enrolled

A Study of Iron Oligosaccharide in Chronic Kidney Disease Patients

Completed·PPharmacosmos A/S·Phase 3·NCT00536666·182 enrolled

Iron Isomaltoside 1000 (Monofer®) in Non-Dialysis Dependent Chronic Kidney Disease and With Renal-Related Anaemia

Completed·PPharmacosmos A/S·Phase 3·NCT01102413·351 enrolled

Intravenous3 trials

A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Iron-deficient Blood Donors

Completed·PPharmacosmos A/S·Phase 3·NCT01895231·107 enrolled

Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous to Patients With CKD

Completed·PPharmacosmos A/S·Phase 1·NCT01213992·16 enrolled

IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose

Completed·PPharmacosmos A/S·Phase 3·NCT02130063·511 enrolled

Hypophosphatemia2 trials

Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

Completed·PPharmacosmos A/S·Phase 3·NCT03238911·123 enrolled

Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

Completed·PPharmacosmos A/S·Phase 3·NCT03237065·122 enrolled

Inflammatory Bowel Disease2 trials

Iron Isomaltoside 1000 (Monofer®) Administered by a High Dosing Regimen in Subjects With Inflammatory Bowel Disease

Completed·PPharmacosmos A/S·Phase 3·NCT01599702·21 enrolled

Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia

Completed·PPharmacosmos A/S·Phase 3·NCT01017614·350 enrolled

Anemia2 trials

Single Dose Intravenous Iron Isomaltoside in Combination With Oral Iron vs Oral Iron Monotherapy in Patients With Anemia After Postpartum Haemorrhage

Unknown status·UUniversity of Malaya·Phase 4·NCT04505514·60 enrolled

Use of Iron Isomaltoside 1000 (Monofer) in Postpartum Anemia

Completed·—·N/A·NCT01628770·271 enrolled

21 more indications

Treatment2 trials

Treatment of Women After Postpartum Haemorrhage

Completed·PPharmacosmos A/S·Phase 3·NCT01895218·200 enrolled

Treatment of Women After Severe Postpartum Haemorrhage

Completed·PPharmacosmos A/S·Phase 3·NCT01895205·13 enrolled

Myeloid Malignancies1 trial

A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)

Completed·PPharmacosmos A/S·Phase 3·NCT01145638·350 enrolled

Chronic Cough1 trial

Iron Repletion in Chronic Cough and Iron Deficiency

Completed·UUniversity of Turin, Italy·N/A·NCT01507792·22 enrolled

Trial1 trial

An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)

Completed·PPharmacosmos A/S·Phase 3·NCT02962648·103 enrolled

Valvular Heart Surgery1 trial

Effect of Perioperative Iron Isomaltoside 1000 Administration on Transfusion Requirements in Patients Undergoing Complex Valvular Heart Surgery: a Randomized Clinical Trial

Completed·YYonsei University·N/A·NCT02862665·214 enrolled

Gastric1 trial

Iron Replacement in Oesophagogastric Neoplasia

Unknown status·NNottingham University Hospitals NHS Trust·Phase 4·NCT01927328·40 enrolled

Cardiac Transplant1 trial

Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients

Completed·OOslo University Hospital·Phase 2/3·NCT03662789·102 enrolled

Hematological Malignancies1 trial

Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)

Completed·PPharmacosmos A/S·Phase 1·NCT01213979·16 enrolled

Total Knee Arthroplasty1 trial

Effect of IV Iron Isomaltoside on Postoperative Anemia in Total Knee Arthroplasty Patients

Completed·SSeoul National University Hospital·N/A·NCT03470649·100 enrolled

MPA1 trial

A Study Comparing the Iron Substitution With the Medicinal Products Ferinject or Monofer

Completed·UUniversität des Saarlandes·Phase 4·NCT02905539·26 enrolled

Restless Legs Syndrome1 trial

IV Iron Treatment of Restless Legs Syndrome

Withdrawn·PPharmacosmos A/S·Phase 2·NCT02484768

OSA1 trial

A Study of Iron Oligosaccharide in CHF Patients

Completed·PPharmacosmos A/S·Phase 3·NCT00537186·20 enrolled

Coronary Artery Bypass1 trial

A Prospective, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Non-Anaemic Patients Undergoing Elective or Sub-Acute Coronary Artery Bypass Graft, Valve Replacement or a Combination Thereof

Completed·PPharmacosmos A/S·Phase 3·NCT01563367·74 enrolled

Hip Fracture1 trial

HiFIT Study : Hip Fracture: Iron and Tranexamic Acid

Terminated·UUniversity Hospital, Angers·Phase 3·NCT02972294·419 enrolled

Orthognathic Surgery1 trial

Efficacy of Intravenous Iron Therapy in Maintaining Hemoglobin Concentration on Patients Undergoing Bimaxillary Orthognathic Surgery

Unknown status·YYonsei University·N/A·NCT03094182·58 enrolled

Heart Failure1 trial

Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE).

Completed·PPierre Fabre Pharma GmbH··NCT04318405·327 enrolled

Pregnancy1 trial

Intravenous Iron Isomaltoside Versus Oral Iron Supplementation for Treatment of Iron Deficiency in Pregnancy.

Completed·PPharmacosmos A/S·Phase 4·NCT03188445·201 enrolled

Blood Transfusion1 trial

Effect of Intravenous Iron Supplementation in Reducing Allogenic Blood Transfusion

Completed·—·Phase 1·NCT04061655·80 enrolled

Iron deficiency anemia1 trial

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)

Completed·PPharmacosmos A/S·Phase 3·NCT02940886·1,512 enrolled

Nasopharyngeal Carcinoma1 trial

Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma

Recruiting·SSun Yat-sen University·Phase 2·NCT05913414·120 enrolled

Double-blind1 trial

A Randomized, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo

Withdrawn·PPharmacosmos A/S·Phase 3·NCT02172001

Sources

References

[1]
ClinicalTrials.gov — 34 trial records for iron sulphate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — iron sulphate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for iron sulphate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pierre Fabre Pharma GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPierre Fabre Pharma GmbH

iron sulphate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Kidney Disease3 trials

Intravenous3 trials

Hypophosphatemia2 trials

Inflammatory Bowel Disease2 trials

Anemia2 trials

Treatment2 trials

Myeloid Malignancies1 trial

Chronic Cough1 trial

Trial1 trial

Valvular Heart Surgery1 trial

Gastric1 trial

Cardiac Transplant1 trial

Hematological Malignancies1 trial

Total Knee Arthroplasty1 trial

MPA1 trial

Restless Legs Syndrome1 trial

OSA1 trial

Coronary Artery Bypass1 trial

Hip Fracture1 trial

Orthognathic Surgery1 trial

Heart Failure1 trial

Pregnancy1 trial

Blood Transfusion1 trial

Iron deficiency anemia1 trial

Nasopharyngeal Carcinoma1 trial

Double-blind1 trial

References

Drug Info

Quick Facts

Related News